The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Companion Cancer Diagnostics Market Research Report 2025
Synopsis
A Companion Cancer Diagnostics is a diagnostic test used as a companion to a therapeutic drug to determine its applicability to a specific person.
Companion Cancer Diagnostics are co-developed with drugs to aid in selecting or excluding patient groups for treatment with that particular drug on the basis of their biological characteristics that determine responders and non-responders to the therapy.
The global Companion Cancer Diagnostics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Companion Cancer Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Companion Cancer Diagnostics.
Report Scope
The Companion Cancer Diagnostics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Companion Cancer Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Companion Cancer Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
F. Hoffmann-La Roche
Agilent Technologies
QIAGEN
Abbott Laboratories
Almac Group
Danaher Corporation
bioMérieuxSA
Myriad Genetics
Segment by Type
Breast Cancer
Lung Cancer
Colorectal Cancer
Melanoma
Gastric Cancer
Segment by Application
Pharmaceutical & Biopharmaceutical Companies
Reference Laboratories
CROs
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Companion Cancer Diagnostics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
A Companion Cancer Diagnostics is a diagnostic test used as a companion to a therapeutic drug to determine its applicability to a specific person.
Companion Cancer Diagnostics are co-developed with drugs to aid in selecting or excluding patient groups for treatment with that particular drug on the basis of their biological characteristics that determine responders and non-responders to the therapy.
The global Companion Cancer Diagnostics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Companion Cancer Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Companion Cancer Diagnostics.
Report Scope
The Companion Cancer Diagnostics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Companion Cancer Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Companion Cancer Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
F. Hoffmann-La Roche
Agilent Technologies
QIAGEN
Abbott Laboratories
Almac Group
Danaher Corporation
bioMérieuxSA
Myriad Genetics
Segment by Type
Breast Cancer
Lung Cancer
Colorectal Cancer
Melanoma
Gastric Cancer
Segment by Application
Pharmaceutical & Biopharmaceutical Companies
Reference Laboratories
CROs
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Companion Cancer Diagnostics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Companion Cancer Diagnostics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Breast Cancer
1.2.3 Lung Cancer
1.2.4 Colorectal Cancer
1.2.5 Melanoma
1.2.6 Gastric Cancer
1.3 Market by Application
1.3.1 Global Companion Cancer Diagnostics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Pharmaceutical & Biopharmaceutical Companies
1.3.3 Reference Laboratories
1.3.4 CROs
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Companion Cancer Diagnostics Market Perspective (2019-2030)
2.2 Companion Cancer Diagnostics Growth Trends by Region
2.2.1 Global Companion Cancer Diagnostics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Companion Cancer Diagnostics Historic Market Size by Region (2019-2024)
2.2.3 Companion Cancer Diagnostics Forecasted Market Size by Region (2025-2030)
2.3 Companion Cancer Diagnostics Market Dynamics
2.3.1 Companion Cancer Diagnostics Industry Trends
2.3.2 Companion Cancer Diagnostics Market Drivers
2.3.3 Companion Cancer Diagnostics Market Challenges
2.3.4 Companion Cancer Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Companion Cancer Diagnostics Players by Revenue
3.1.1 Global Top Companion Cancer Diagnostics Players by Revenue (2019-2024)
3.1.2 Global Companion Cancer Diagnostics Revenue Market Share by Players (2019-2024)
3.2 Global Companion Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Companion Cancer Diagnostics Revenue
3.4 Global Companion Cancer Diagnostics Market Concentration Ratio
3.4.1 Global Companion Cancer Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Companion Cancer Diagnostics Revenue in 2023
3.5 Companion Cancer Diagnostics Key Players Head office and Area Served
3.6 Key Players Companion Cancer Diagnostics Product Solution and Service
3.7 Date of Enter into Companion Cancer Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Companion Cancer Diagnostics Breakdown Data by Type
4.1 Global Companion Cancer Diagnostics Historic Market Size by Type (2019-2024)
4.2 Global Companion Cancer Diagnostics Forecasted Market Size by Type (2025-2030)
5 Companion Cancer Diagnostics Breakdown Data by Application
5.1 Global Companion Cancer Diagnostics Historic Market Size by Application (2019-2024)
5.2 Global Companion Cancer Diagnostics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Companion Cancer Diagnostics Market Size (2019-2030)
6.2 North America Companion Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Companion Cancer Diagnostics Market Size by Country (2019-2024)
6.4 North America Companion Cancer Diagnostics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Companion Cancer Diagnostics Market Size (2019-2030)
7.2 Europe Companion Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Companion Cancer Diagnostics Market Size by Country (2019-2024)
7.4 Europe Companion Cancer Diagnostics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Companion Cancer Diagnostics Market Size (2019-2030)
8.2 Asia-Pacific Companion Cancer Diagnostics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Companion Cancer Diagnostics Market Size by Region (2019-2024)
8.4 Asia-Pacific Companion Cancer Diagnostics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Companion Cancer Diagnostics Market Size (2019-2030)
9.2 Latin America Companion Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Companion Cancer Diagnostics Market Size by Country (2019-2024)
9.4 Latin America Companion Cancer Diagnostics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Companion Cancer Diagnostics Market Size (2019-2030)
10.2 Middle East & Africa Companion Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Companion Cancer Diagnostics Market Size by Country (2019-2024)
10.4 Middle East & Africa Companion Cancer Diagnostics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 F. Hoffmann-La Roche
11.1.1 F. Hoffmann-La Roche Company Detail
11.1.2 F. Hoffmann-La Roche Business Overview
11.1.3 F. Hoffmann-La Roche Companion Cancer Diagnostics Introduction
11.1.4 F. Hoffmann-La Roche Revenue in Companion Cancer Diagnostics Business (2019-2024)
11.1.5 F. Hoffmann-La Roche Recent Development
11.2 Agilent Technologies
11.2.1 Agilent Technologies Company Detail
11.2.2 Agilent Technologies Business Overview
11.2.3 Agilent Technologies Companion Cancer Diagnostics Introduction
11.2.4 Agilent Technologies Revenue in Companion Cancer Diagnostics Business (2019-2024)
11.2.5 Agilent Technologies Recent Development
11.3 QIAGEN
11.3.1 QIAGEN Company Detail
11.3.2 QIAGEN Business Overview
11.3.3 QIAGEN Companion Cancer Diagnostics Introduction
11.3.4 QIAGEN Revenue in Companion Cancer Diagnostics Business (2019-2024)
11.3.5 QIAGEN Recent Development
11.4 Abbott Laboratories
11.4.1 Abbott Laboratories Company Detail
11.4.2 Abbott Laboratories Business Overview
11.4.3 Abbott Laboratories Companion Cancer Diagnostics Introduction
11.4.4 Abbott Laboratories Revenue in Companion Cancer Diagnostics Business (2019-2024)
11.4.5 Abbott Laboratories Recent Development
11.5 Almac Group
11.5.1 Almac Group Company Detail
11.5.2 Almac Group Business Overview
11.5.3 Almac Group Companion Cancer Diagnostics Introduction
11.5.4 Almac Group Revenue in Companion Cancer Diagnostics Business (2019-2024)
11.5.5 Almac Group Recent Development
11.6 Danaher Corporation
11.6.1 Danaher Corporation Company Detail
11.6.2 Danaher Corporation Business Overview
11.6.3 Danaher Corporation Companion Cancer Diagnostics Introduction
11.6.4 Danaher Corporation Revenue in Companion Cancer Diagnostics Business (2019-2024)
11.6.5 Danaher Corporation Recent Development
11.7 bioMérieuxSA
11.7.1 bioMérieuxSA Company Detail
11.7.2 bioMérieuxSA Business Overview
11.7.3 bioMérieuxSA Companion Cancer Diagnostics Introduction
11.7.4 bioMérieuxSA Revenue in Companion Cancer Diagnostics Business (2019-2024)
11.7.5 bioMérieuxSA Recent Development
11.8 Myriad Genetics
11.8.1 Myriad Genetics Company Detail
11.8.2 Myriad Genetics Business Overview
11.8.3 Myriad Genetics Companion Cancer Diagnostics Introduction
11.8.4 Myriad Genetics Revenue in Companion Cancer Diagnostics Business (2019-2024)
11.8.5 Myriad Genetics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Companion Cancer Diagnostics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Breast Cancer
Table 3. Key Players of Lung Cancer
Table 4. Key Players of Colorectal Cancer
Table 5. Key Players of Melanoma
Table 6. Key Players of Gastric Cancer
Table 7. Global Companion Cancer Diagnostics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Companion Cancer Diagnostics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 9. Global Companion Cancer Diagnostics Market Size by Region (2019-2024) & (US$ Million)
Table 10. Global Companion Cancer Diagnostics Market Share by Region (2019-2024)
Table 11. Global Companion Cancer Diagnostics Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 12. Global Companion Cancer Diagnostics Market Share by Region (2025-2030)
Table 13. Companion Cancer Diagnostics Market Trends
Table 14. Companion Cancer Diagnostics Market Drivers
Table 15. Companion Cancer Diagnostics Market Challenges
Table 16. Companion Cancer Diagnostics Market Restraints
Table 17. Global Companion Cancer Diagnostics Revenue by Players (2019-2024) & (US$ Million)
Table 18. Global Companion Cancer Diagnostics Market Share by Players (2019-2024)
Table 19. Global Top Companion Cancer Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Companion Cancer Diagnostics as of 2023)
Table 20. Ranking of Global Top Companion Cancer Diagnostics Companies by Revenue (US$ Million) in 2023
Table 21. Global 5 Largest Players Market Share by Companion Cancer Diagnostics Revenue (CR5 and HHI) & (2019-2024)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Companion Cancer Diagnostics Product Solution and Service
Table 24. Date of Enter into Companion Cancer Diagnostics Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Companion Cancer Diagnostics Market Size by Type (2019-2024) & (US$ Million)
Table 27. Global Companion Cancer Diagnostics Revenue Market Share by Type (2019-2024)
Table 28. Global Companion Cancer Diagnostics Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 29. Global Companion Cancer Diagnostics Revenue Market Share by Type (2025-2030)
Table 30. Global Companion Cancer Diagnostics Market Size by Application (2019-2024) & (US$ Million)
Table 31. Global Companion Cancer Diagnostics Revenue Market Share by Application (2019-2024)
Table 32. Global Companion Cancer Diagnostics Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 33. Global Companion Cancer Diagnostics Revenue Market Share by Application (2025-2030)
Table 34. North America Companion Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. North America Companion Cancer Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 36. North America Companion Cancer Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 37. Europe Companion Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 38. Europe Companion Cancer Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 39. Europe Companion Cancer Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 40. Asia-Pacific Companion Cancer Diagnostics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 41. Asia-Pacific Companion Cancer Diagnostics Market Size by Region (2019-2024) & (US$ Million)
Table 42. Asia-Pacific Companion Cancer Diagnostics Market Size by Region (2025-2030) & (US$ Million)
Table 43. Latin America Companion Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Latin America Companion Cancer Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 45. Latin America Companion Cancer Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 46. Middle East & Africa Companion Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 47. Middle East & Africa Companion Cancer Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 48. Middle East & Africa Companion Cancer Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 49. F. Hoffmann-La Roche Company Detail
Table 50. F. Hoffmann-La Roche Business Overview
Table 51. F. Hoffmann-La Roche Companion Cancer Diagnostics Product
Table 52. F. Hoffmann-La Roche Revenue in Companion Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 53. F. Hoffmann-La Roche Recent Development
Table 54. Agilent Technologies Company Detail
Table 55. Agilent Technologies Business Overview
Table 56. Agilent Technologies Companion Cancer Diagnostics Product
Table 57. Agilent Technologies Revenue in Companion Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 58. Agilent Technologies Recent Development
Table 59. QIAGEN Company Detail
Table 60. QIAGEN Business Overview
Table 61. QIAGEN Companion Cancer Diagnostics Product
Table 62. QIAGEN Revenue in Companion Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 63. QIAGEN Recent Development
Table 64. Abbott Laboratories Company Detail
Table 65. Abbott Laboratories Business Overview
Table 66. Abbott Laboratories Companion Cancer Diagnostics Product
Table 67. Abbott Laboratories Revenue in Companion Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 68. Abbott Laboratories Recent Development
Table 69. Almac Group Company Detail
Table 70. Almac Group Business Overview
Table 71. Almac Group Companion Cancer Diagnostics Product
Table 72. Almac Group Revenue in Companion Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 73. Almac Group Recent Development
Table 74. Danaher Corporation Company Detail
Table 75. Danaher Corporation Business Overview
Table 76. Danaher Corporation Companion Cancer Diagnostics Product
Table 77. Danaher Corporation Revenue in Companion Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 78. Danaher Corporation Recent Development
Table 79. bioMérieuxSA Company Detail
Table 80. bioMérieuxSA Business Overview
Table 81. bioMérieuxSA Companion Cancer Diagnostics Product
Table 82. bioMérieuxSA Revenue in Companion Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 83. bioMérieuxSA Recent Development
Table 84. Myriad Genetics Company Detail
Table 85. Myriad Genetics Business Overview
Table 86. Myriad Genetics Companion Cancer Diagnostics Product
Table 87. Myriad Genetics Revenue in Companion Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 88. Myriad Genetics Recent Development
Table 89. Research Programs/Design for This Report
Table 90. Key Data Information from Secondary Sources
Table 91. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Companion Cancer Diagnostics Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Companion Cancer Diagnostics Market Share by Type: 2023 VS 2030
Figure 3. Breast Cancer Features
Figure 4. Lung Cancer Features
Figure 5. Colorectal Cancer Features
Figure 6. Melanoma Features
Figure 7. Gastric Cancer Features
Figure 8. Global Companion Cancer Diagnostics Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 9. Global Companion Cancer Diagnostics Market Share by Application: 2023 VS 2030
Figure 10. Pharmaceutical & Biopharmaceutical Companies Case Studies
Figure 11. Reference Laboratories Case Studies
Figure 12. CROs Case Studies
Figure 13. Others Case Studies
Figure 14. Companion Cancer Diagnostics Report Years Considered
Figure 15. Global Companion Cancer Diagnostics Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 16. Global Companion Cancer Diagnostics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 17. Global Companion Cancer Diagnostics Market Share by Region: 2023 VS 2030
Figure 18. Global Companion Cancer Diagnostics Market Share by Players in 2023
Figure 19. Global Top Companion Cancer Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Companion Cancer Diagnostics as of 2023)
Figure 20. The Top 10 and 5 Players Market Share by Companion Cancer Diagnostics Revenue in 2023
Figure 21. North America Companion Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. North America Companion Cancer Diagnostics Market Share by Country (2019-2030)
Figure 23. United States Companion Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Canada Companion Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe Companion Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Europe Companion Cancer Diagnostics Market Share by Country (2019-2030)
Figure 27. Germany Companion Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. France Companion Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. U.K. Companion Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Italy Companion Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Russia Companion Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Nordic Countries Companion Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Asia-Pacific Companion Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Asia-Pacific Companion Cancer Diagnostics Market Share by Region (2019-2030)
Figure 35. China Companion Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Japan Companion Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. South Korea Companion Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Southeast Asia Companion Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. India Companion Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Australia Companion Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Latin America Companion Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Latin America Companion Cancer Diagnostics Market Share by Country (2019-2030)
Figure 43. Mexico Companion Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Brazil Companion Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa Companion Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Middle East & Africa Companion Cancer Diagnostics Market Share by Country (2019-2030)
Figure 47. Turkey Companion Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Saudi Arabia Companion Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. F. Hoffmann-La Roche Revenue Growth Rate in Companion Cancer Diagnostics Business (2019-2024)
Figure 50. Agilent Technologies Revenue Growth Rate in Companion Cancer Diagnostics Business (2019-2024)
Figure 51. QIAGEN Revenue Growth Rate in Companion Cancer Diagnostics Business (2019-2024)
Figure 52. Abbott Laboratories Revenue Growth Rate in Companion Cancer Diagnostics Business (2019-2024)
Figure 53. Almac Group Revenue Growth Rate in Companion Cancer Diagnostics Business (2019-2024)
Figure 54. Danaher Corporation Revenue Growth Rate in Companion Cancer Diagnostics Business (2019-2024)
Figure 55. bioMérieuxSA Revenue Growth Rate in Companion Cancer Diagnostics Business (2019-2024)
Figure 56. Myriad Genetics Revenue Growth Rate in Companion Cancer Diagnostics Business (2019-2024)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
